Jazz Pharmaceuticals (JAZZ) announced that the European Commission has granted conditional marketing authorization for Ziihera, a dual human epidermal growth factor receptor 2-targeted bispecific antibody, as monotherapy for the treatment of adults with unresectable locally advanced or metastatic HER2-positive biliary tract cancer previously treated with at least one prior line of systemic therapy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals’ Pregnancy Surveillance Study: A Key Update for Investors
- Jazz Pharmaceuticals Completes Key Study on Zepzelca for SCLC
- Avadel announces appeals court decision upholding FDA approval of LUMRYZ
- Jazz Pharmaceuticals and BeiGene’s Promising Phase 3 Study for Advanced Gastric and Esophageal Cancers
- Jazz Pharmaceuticals’ Zanidatamab Study: A Potential Game-Changer in HER2 Cancer Treatment